These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 20605645)

  • 21. Novel anti-arrhythmic agents for the treatment of atrial fibrillation.
    Wettwer E; Christ T; Dobrev D; Ravens U
    Curr Opin Pharmacol; 2007 Apr; 7(2):214-8. PubMed ID: 17303472
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dronedarone.
    Patel C; Yan GX; Kowey PR
    Circulation; 2009 Aug; 120(7):636-44. PubMed ID: 19687370
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dronedarone: an emerging therapy for atrial fibrillation.
    Rosei EA; Salvetti M
    Ther Adv Cardiovasc Dis; 2010 Jun; 4(3):155-64. PubMed ID: 20418270
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vernakalant hydrochloride for the treatment of atrial fibrillation.
    Kozlowski D; Budrejko S; Lip GY; Mikhailidis DP; Rysz J; Raczak G; Banach M
    Expert Opin Investig Drugs; 2009 Dec; 18(12):1929-37. PubMed ID: 19938903
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeted pharmacological reversal of electrical remodeling after cardioversion--rationale and design of the Flecainide Short-Long (Flec-SL) trial.
    Kirchhof P; Fetsch T; Hanrath P; Meinertz T; Steinbeck G; Lehmacher W; Breithardt G
    Am Heart J; 2005 Nov; 150(5):899. PubMed ID: 16290956
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Atorvastatin treatment affects atrial ion currents and their tachycardia-induced remodeling in rabbits.
    Laszlo R; Menzel KA; Bentz K; Schreiner B; Kettering K; Eick C; Schreieck J
    Life Sci; 2010 Oct; 87(15-16):507-13. PubMed ID: 20851131
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Morphological remodeling in atrial fibrillation].
    Goette A; Lendeckel U
    Herz; 2006 Apr; 31(2):101-7; quiz 142-3. PubMed ID: 16738831
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of chronic gap junction conduction-enhancing antiarrhythmic peptide GAP-134 administration on experimental atrial fibrillation in dogs.
    Laurent G; Leong-Poi H; Mangat I; Moe GW; Hu X; So PP; Tarulli E; Ramadeen A; Rossman EI; Hennan JK; Dorian P
    Circ Arrhythm Electrophysiol; 2009 Apr; 2(2):171-8. PubMed ID: 19808462
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Pharmacological restoration and maintenance of sinus rhythm by antiarrhythmic agents].
    Sugi K
    J Cardiol; 1999 Mar; 33 Suppl 1():59-64. PubMed ID: 10342138
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cardiac ion channels and mechanisms for protection against atrial fibrillation.
    Grunnet M; Bentzen BH; Sørensen US; Diness JG
    Rev Physiol Biochem Pharmacol; 2012; 162():1-58. PubMed ID: 21987061
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Management of atrial fibrillation.
    Hersi A; Wyse DG
    Curr Probl Cardiol; 2005 Apr; 30(4):175-233. PubMed ID: 15778690
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Drug therapy for termination of atrial fibrillation and maintenance of sinus rhythm.
    Talajic M; Roy D
    Can J Cardiol; 2005 Sep; 21 Suppl B():19B-25B. PubMed ID: 16239983
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacologic approaches to rhythm versus rate control in atrial fibrillation--where are we now?
    Wyse DG
    Int J Cardiol; 2006 Jun; 110(3):301-12. PubMed ID: 16516313
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Non-channel drugs to prevent atrial fibrillation].
    Fazekas T; Liszkai G
    Orv Hetil; 2005 Nov; 146(45):2287-94. PubMed ID: 16304807
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The emerging role of antiarrhythmic compounds with atrial selectivity in the management of atrial fibrillation.
    McBride BF
    J Clin Pharmacol; 2009 Mar; 49(3):258-67. PubMed ID: 19246727
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hybrid therapy of atrial fibrillation.
    Santini M; Pignalberi C; Ricci R; Calò L
    Ital Heart J; 2002 Oct; 3(10):571-8. PubMed ID: 12478814
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Atrial fibrillation: drug therapies for ventricular rate control and restoration of sinus rhythm.
    Chandramouli BV; Kotler MN
    Geriatrics; 1998 Jun; 53(6):46-8, 51-2, 54, 57-60. PubMed ID: 9634106
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The gap junction modifier, GAP-134 [(2S,4R)-1-(2-aminoacetyl)-4-benzamido-pyrrolidine-2-carboxylic acid], improves conduction and reduces atrial fibrillation/flutter in the canine sterile pericarditis model.
    Rossman EI; Liu K; Morgan GA; Swillo RE; Krueger JA; Gardell SJ; Butera J; Gruver M; Kantrowitz J; Feldman HS; Petersen JS; Haugan K; Hennan JK
    J Pharmacol Exp Ther; 2009 Jun; 329(3):1127-33. PubMed ID: 19252062
    [TBL] [Abstract][Full Text] [Related]  

  • 39. New antiarrhythmic drugs for establishing sinus rhythm in atrial fibrillation: what are our therapies likely to be by 2010 and beyond?
    Morrow JP; Cannon CP; Reiffel JA
    Am Heart J; 2007 Nov; 154(5):824-9. PubMed ID: 17967585
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of amiodarone on electrical and structural remodeling induced in a canine rapid pacing-induced persistent atrial fibrillation model.
    Ashikaga K; Kobayashi T; Kimura M; Owada S; Sasaki S; Iwasa A; Furukawa K; Motomura S; Okumura K
    Eur J Pharmacol; 2006 Apr; 536(1-2):148-53. PubMed ID: 16556442
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.